Holen Sie sich die Stockscreener-App
9.59
7.03%
0.63
Handel nachbörslich:
9.40
-0.19
-1.98%
Schlusskurs vom Vortag:
$8.96
Offen:
$8.9
24-Stunden-Volumen:
153.98K
Relative Volume:
1.04
Marktkapitalisierung:
$117.53M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-38.70M
KGV:
-2.0535
EPS:
-4.67
Netto-Cashflow:
$-36.86M
1W Leistung:
+5.27%
1M Leistung:
+15.96%
6M Leistung:
+1.16%
1J Leistung:
-81.90%
1-Tages-Spanne:
$8.90
$9.68
1-Wochen-Bereich:
$8.37
$9.68
52-Wochen-Spanne:
$4.64
$61.89
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Vergleichen Sie CRBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.59 | 109.81M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
What is the next catalyst for Corbus Pharmaceuticals Holdings Inc.Free Trading Indicator Pack - thegnnews.com
Can Cannabis Stocks Reverse Their Prolonged Downtrend? - The Globe and Mail
Oppenheimer Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00 - Defense World
Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates - TipRanks
William Blair Issues Negative Outlook for CRBP Earnings - Defense World
Using flow based indicators on Corbus Pharmaceuticals Holdings Inc.Free Real Time Stock Movement Analysis - Newser
How moving averages guide Corbus Pharmaceuticals Holdings Inc. tradingSwing Candidate List with Trade Cues - Newser
Oppenheimer Maintains Outperform Rating for CRBP with Lowered Price Target of $53.00 - AInvest
Oppenheimer Maintains Outperform Rating for CRBP, Lowers Price T - GuruFocus
Corbus Pharmaceuticals: Q2 Earnings Snapshot - New Haven Register
Corbus (CRBP) Q2 Loss Beats Estimates - AOL.com
Key metrics from Corbus Pharmaceuticals Holdings Inc.’s quarterly dataSummary of Long-Term Buy Zone Stocks - Newser
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Receives FDA Fast Track Designation - TipRanks
Corbus Pharmaceuticals Q2 basic eps usd -1.44 - MarketScreener
Corbus Pharmaceuticals (CRBP) Gears Up for Pivotal Data Presentations in Late 2025 - GuruFocus
Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | CRBP Stock News - GuruFocus
Corbus Advances 3 Clinical Programs: Obesity Drug Trial Expands, Cancer Data Coming to ESMO - Stock Titan
Is Corbus Pharmaceuticals Holdings Inc. stock overvalued or undervaluedBuild wealth steadily with smart trading - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a growth stock or a value stockSkyrocketing investment returns - Jammu Links News
Is Corbus Pharmaceuticals Holdings Inc. a good long term investmentFree Stock Market Return Analysis - Jammu Links News
What is the risk reward ratio of investing in Corbus Pharmaceuticals Holdings Inc. stockGet timely alerts on market opportunities - Jammu Links News
Is it the right time to buy Corbus Pharmaceuticals Holdings Inc. stockExplosive portfolio gains - Jammu Links News
What are the latest earnings results for Corbus Pharmaceuticals Holdings Inc.Superior profit margins - Jammu Links News
When is Corbus Pharmaceuticals Holdings Inc. stock expected to show significant growthDiscover breakthrough stocks before the crowd - Jammu Links News
What analysts say about Corbus Pharmaceuticals Holdings Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are Corbus Pharmaceuticals Holdings Inc. company’s key revenue driversFree Stock Review Backed By Experts - Jammu Links News
What is B. Riley’s Forecast for CRBP Q2 Earnings? - Defense World
What is the dividend policy of Corbus Pharmaceuticals Holdings Inc. stockFinancial News Target Finder For Smart Trading - Jammu Links News
Why is Corbus Pharmaceuticals Holdings Inc. stock attracting strong analyst attentionReal Time Tracker For Fast Growth - Jammu Links News
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of “Buy” by Brokerages - Defense World
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance By Investing.com - Investing.com Australia
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Corbus Pharmaceuticals Announces Upcoming Presentation of - GlobeNewswire
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 By Investing.com - Investing.com South Africa
Corbus to present updated CRB-701 cancer drug data at ESMO 2025 - Investing.com Nigeria
Corbus Pharmaceuticals stock rises after ESMO abstract acceptance - Investing.com
CRBP: B. Riley Maintains Buy Rating with Promising Drug Potential - GuruFocus
Corbus Pharmaceuticals (CRBP) to Present Phase 1/2 Study Data at ESMO 2025 - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose E - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress | CRBP Stock News - GuruFocus
Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress - GlobeNewswire
Latest Clinical Data: Corbus' Next-Gen Cancer Drug Targets Multiple Advanced TumorsESMO 2025 Preview - Stock Titan
Strategies to average down on Corbus Pharmaceuticals Holdings Inc.Real Time Growth Signal with Smart Setup - Newser
How to build a custom watchlist for Corbus Pharmaceuticals Holdings Inc.Buy Opportunity Forecast for Fast Traders - Newser
Has Corbus Pharmaceuticals Holdings Inc. Stock Ever Crashed Historical Volatility ReviewDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
How Corbus Pharmaceuticals Holdings Inc. stock performs during market volatilityFree Wealth Building Stock Market Ideas - Newser
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):